WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause
Notified -
Globe Newswire8-07-2025, 17:30
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26